Nine Months: A Timeline Split by Policy
For the first time, the **** spot belonged not to an RF device but to a "lamp."
This is a signal: consumers buy not a technical term but "which specific concern it solves."
Low and high prices coexisted, pulling the average price back and forth.
It directly amplified April's decline.
At midnight, Taobao/Tmall, Douyin, and JD.com completed bulk removal of uncertified products.
RF products from brands such as AMIRO, YA-MAN, Huazhi, and Tripollar collectively disappeared.
As of that month, only 12 companies nationwide held certificates, of which 9 were registered for "home environment self-use."
Volume and price both fell, but the decline mainly came from average price.
RF had concentrated in the 2,000–7,000 RMB range, and its disappearance directly removed the industry's price ceiling.
Douyin channel share rose to 65.1%, while platform e-commerce fell to 24.0%.
The higher the share of high-priced RF, the heavier the bleeding.
The policy context for eye care consumption shifted from "treatment" to "full-lifecycle eye health management."
At the same time, kindergartens are required to conduct vision screenings every six months and primary/secondary schools twice per semester—screening frequency was institutionalized.
The combination of device + clinical-grade essence lent the trust of a "device" to an "instrument."
The eye-care line continued product iteration (See 7RS launched, See 7C updated), but high gross margin and high expenses were offsetting each other.
As a Class II medical device, eye care devices are registered only for "relieving visual fatigue." Any claim of "reducing prescription" or "replacing OK lenses" is a violation.
Only 330 million RMB in the month
−29.3% MoM
9 of them for home use
Brand loyalty nearly zero
A "Volume-Price Divergence" Structural Rebuilding
This divergence is usually read as "consumption upgrading," but this time it is not—it is the result of remaining supply being repriced after high-priced supply was administratively cleared.
January absolute value not disclosed; back-calculated from Q1 total of 1.29 billion RMB and Feb–Mar data to approximately 90 million RMB.
Fact 01 | What disappeared was not demand, but the price band.
April retail volume fell only 22.2%, but retail sales fell 45.0%.
The difference all came from average price: from 1,695 RMB straight down to 1,198 RMB, a 29.3% drop.
RF originally occupied the 2,000–7,000 RMB range, and its collective delisting removed the industry ceiling in one stroke.
This also explains why May could rebound to 900 million RMB—the suppressed average price was pushed back up by high-end non-RF models (large LED panels, hydro devices) during 618.
Fact 02 | Channel divergence outweighed category divergence.
In April, Douyin's retail sales share was 65.1% (+3.3pt), retail volume share 74.8% (+6.3pt), average price 1,042 RMB (−31.8%).
Platform e-commerce share fell to 24.0% (−5.8pt), retail sales down 55.7% MoM, and the number of brands decreased by 10.
The rule is clear: the higher the share of high-priced RF products in a channel, the heavier the damage.
Douyin used low-priced non-RF products to absorb the released demand, at the cost of permanently lowering the average price.
Fact 03 | Ranking reshuffling was unprecedented.
In Q2, 13 of the TOP20 products were new entrants, a new entry rate of 65%.
This is a shelf with almost no brand loyalty—consumers' decision unit is "a specific concern + a specific technology," not "a specific brand."
Implication for brands: the window for a single hit product is shortening, and the model of living off one product for three years has failed.
Fact 04 | The full-year base was actually shrinking.
Zoom out: in full-year 2025, beauty device sales across Taobao/Tmall, JD.com, and Douyin totaled 20.857 billion RMB, down 11.1% YoY.
Volume was 114 million units, down 11.6% YoY.
Only one subcategory—"device accessories"—was growing.
2026's high growth is largely a combination of base effects and structural upgrading, not an expansion of total demand.
This determines that Q4 cannot be treated as a "boom cycle" for stocking.
One Leader, Two Strong Players, and a Group of Certificate Holders
A considerable portion of Jmoon's 30.3% share comes from the vacuum left by competitors' delisting, not from a victory in brand equity.
| Brand | Retail Sales | Retail Volume | Share | MoM Change | Avg. Price | Technology Route & Key Actions |
|---|---|---|---|---|---|---|
| Jmoon | 570M RMB | 220K units | 30.3% | +6.9 pt | ~2,591 RMB | High current + LED + transdermal collagen light, not constrained by the RF regulation; Douyin channel share 37.6%, 9 of TOP20 spots |
| SEAYEO | 290M RMB | 78K units | 15.6% | +3.1 pt | 3,748 RMB | Large LED panel series as core; platform e-commerce 75.2%, driven by top livestreamer resources |
| GEMO | 150M RMB | 26K units | 8.2% | +2.6 pt | 5,869 RMB | Ultra-high-end + AI narrative; Douyin 85.5%; AI Master Hydro Device at 6,099 RMB still achieving volume |
| YA-MAN | — | — | 6.38% | Sharp decline | — | Already holds Class III certificate, but RF products delisted from April, share fell to fourth |
| MESMOOTH | — | — | ~5.5% (Q1) | — | — | Mid-range value-for-money route |
Note: Q1 top five shares were Jmoon 23.8%, YA-MAN 14.2%, SEAYEO 12.7%, GEMO 5.7%, MESMOOTH 5.5%.
YA-MAN and SEAYEO collectively lost 17.9 percentage points of share in April, forming the most typical "seesaw effect" of this cycle.
- Judgment 1: Jmoon's lead is a compliance dividend lead.
Its core product lines (high current, LED, transdermal collagen light) were never in the regulation's scope.
The window when competitors collectively delisted lasted only one quarter, but it was enough to push share from 23.8% to 30.3%.
The risk is equally clear: its core RF products are in the registration process.
Once certified brands return, a considerable portion of that 30% is "borrowed." - Judgment 2: High-end did not disappear; it changed carriers.
GEMO at 5,869 RMB and SEAYEO at 3,748 RMB still achieved volume during the "high-end vacuum."
GEMO's AI Master Hydro Device at 6,099 RMB still grew, showing that price sensitivity is not among high-end customers but mid-range customers.
What was truly squeezed was the 1,500–3,000 RMB segment: not high enough for professional endorsement, not low enough for value-for-money. - Judgment 3: "Certified" is becoming a new brand asset.
Certified brands such as YA-MAN and Malian have placed Class III medical device registration certificates in the most prominent position on their flagship stores.
Research shows certified products have a 29% higher repurchase rate and 76% lower consumer complaints.
The deeper meaning: qualification has turned from "compliance cost" into "marketing material," which was unimaginable before 2025. - Judgment 4: Top-tier R&D investment up 48% YoY.
In H1 2026, leading beauty device companies increased R&D investment by 48% YoY, focusing on skin simulation AI labs and human clinical testing bases.
R&D focus shifted from appearance and claims to hardware safety, efficacy verification, and AI precise energy control.
This contrasts with Breo's path: the latter invested 23.21 million RMB in R&D and added 98 patents in H1, but revenue was still declining.
R&D is not the current cure; it is the ticket to the next round.
From "Energy Parameters" to "Wavelength + Depth + Verifiability"
After 2026, it became "how many nanometers, how many millimeters of penetration, and can you produce clinical data."
This is a change in discourse system.
2026E is the midpoint of the range; most of the RF share gap is "supply administratively cleared," not demand satisfied.
| Route | Representative Parameters | Action Layer | Eye-Area Suitability | Compliance Status |
|---|---|---|---|---|
| RF | Around 1MHz, epidermal temperature control ≤39.5–40.5℃ | Mid-superficial dermis, about 3.5mm | Periocular skin only about 0.5mm thick, extremely low thermal damage tolerance, requires independent temperature control and automatic shut-off | Since 2026.04.01 included in Class III medical devices, uncertified sales prohibited |
| Transdermal Collagen Light (near-infrared broad band) | 760–1,400nm (deep) + 1,400–1,940nm (shallow); penetration about 4.5mm; 7cm² planar thermal field | Superficial, mid, and deep dermis | Non-contact, space-heating, no electrode fit issues; gradient characteristics of epidermal warmth and dermal heat suit thin-skin areas | Sold as non-RF path, not yet included in Class III; claims constrained by advertising law |
| LED / Phototherapy (633 / 830 / 1064nm) | 633nm red + 830nm near-infrared as basic combination; 1064nm used for deeper "filling collagen" narrative | Red light偏向 epidermis to superficial dermis; 830nm and 1064nm deeper | Non-thermal, non-ablative, highest safety; but requires eye mask protection, efficacy cumulative (6–12 weeks) | Non-RF, currently managed as small appliance; blue light safety controversy not fully resolved, tightening expected |
| Microcurrent / EMS | Biphasic wave, eye safety threshold usually <450µA; multi-frequency alternating | Muscle layer and fascia layer | Immediate lifting and de-puffing feel strong, fast visual feedback, suitable for short-video demos; long-term evidence weak | Managed as small appliance, brands proactively benchmark device safety standards amid tightening expectations |
Another multicenter randomized sham-controlled study showed 86.2% of subjects improved in periorbital wrinkles, versus 16.7% in the control group."
— LED eye-area clinical evidence review (multiple RCT summaries).
This is why brands extensively cite the 633/830 numbers on their detail pages.
- Battlefield 1: Penetration depth, from 3.5mm to 4.5mm.
Transdermal collagen light uses "acting at 4.5mm subcutaneously, reaching superficial, mid, and deep dermis" as its core attack point against RF, and uses a 7cm² planar thermal field against RF's point-electrode thermal field.
A sober view: depth does not equal efficacy.
Depth determines "whether it can reach"; dose and cumulative frequency determine "what happens after reaching." - Battlefield 2: Wavelength refinement, 1064nm's clinical endorsement.
GEMO directly binds 1064nm "filling collagen light" to clinical Fotona 4D's same wavelength, with a 58cm² light energy chamber and 108 lamp beads for dead-angle-free eye coverage.
This is the most effective technology translation of 2026—using a device name familiar to doctors to explain a wavelength consumers do not understand. - Battlefield 3: AI and sensing, from "passive massage" to "active management."
Post-regulation certified products almost all carry multi-layer skin sensors, collecting temperature and tolerance in real time and dynamically adjusting output.
The isomorphic move on the eye side is "one machine, three tests": Breo's dual-spectrum eye care device (899 RMB) simultaneously measures intraocular pressure, periocular moisture, and blink frequency, selling 20,000 units in 30 seconds on Douyin with this test. - Battlefield 4: Safety boundary, the physical constraint of 0.5mm.
Periocular skin is about 0.5mm thick, one of the thinnest areas of the body.
The industry's engineering answers converge on three directions: independent thermistor + over-temperature automatic shut-off (e.g., 39.5℃ cap, 40.5℃ shut-off), non-contact space heating, and low current threshold (<450µA).
These three are becoming the implicit entry barriers for the eye category.
Rigid Demand Sinking, High-End at "Perceivability"
When "compliance" is not a barrier, competition can only return to price and efficacy proof.
| Indicator | Value | Interpretation |
|---|---|---|
| Tmall eye massager category GMV YoY | +27% | Base still growing; cold/hot compress + voice control are high-conversion selling points |
| JD.com self-operated sales share | 38.5% | JD remains the main battleground for brand and trust, with the highest average ticket |
| Livestream incremental contribution | 25% | New product ignition almost entirely happens in livestreams |
| Douyin channel share below 189 RMB | 67% | Low-priced entry models "instantly become hits," but margins are razor-thin |
| Users accepting 100–300 RMB | 38% | Price band highly concentrated in the low-to-mid segment |
| Users accepting 300–500 RMB | 28% | Same as above |
| Proportion switching brands if price rises 10% | 26% | Fragile loyalty; premiumization must be synchronized with perceivable efficacy |
| Regular weekly use (≥3 times) share | 51% | Crossing 60% triggers about 18% capacity expansion |
| "Efficacy-first" user share | 31% | Content narrative should shift from "relaxation" to "intervention" |
| Amazon US "Eye Massager" search volume | +68% YoY | Cold/hot compress function brings about 30% premium; TikTok #eyemassager views over 420 million |
Global size caveat.
Eye massagers: global 2025 narrow caliber (eye mask type) about 654 million USD, broad caliber about 1.387 billion USD, CAGR 8.01%–10.1%.
Some institutions give a broad 2026 global figure of 4.85 billion USD, +12.3% YoY; the statistical scopes differ greatly and cannot be mixed.
China market: eye mask type about 9.9 billion RMB in 2025 (+20%), handheld massager 5.87 billion RMB (+29.3%).
2026 China eye massager/eye care device terminal narrow caliber about 3.5 billion RMB, online GMV estimated 0.93–1.02 billion RMB.
- Strategy 1: Use "detection functions" to support premium.
Breo's dual-spectrum eye care device is priced at 899 RMB, 200 RMB more than the old model, relying on "one machine, three tests" to sell 20,000 units in 30 seconds on Douyin livestream.
The essence is reconstructing a massager into a "readable health terminal."
The more specific the readings, the stronger the justification for premium. - Strategy 2: Use "clinical collaboration" to support trust.
In August, SKG jointly published "Intervention Effect of Hot Compress Massage on Meibomian Gland Dysfunction" with the Zhongshan Ophthalmic Center, showing that after 14 consecutive days of use, tear film breakup time extended by an average of 2.1 seconds.
This is an extremely smart indicator choice: it does not promise to "cure dry eye," only a measurable, reproducible intermediate variable directly related to dry eye. - Strategy 3: Use "channel division" to support profit.
The three-wheel drive of "JD builds brand, Douyin acquires new customers, Tmall accumulates members" has been validated.
SKG, which executed this strategy, increased its sales share in the 189–399 RMB band by 7 percentage points in Q4.
The key action is cutting visual experiment videos into 15-second clips for Douyin, directing traffic to the JD flagship store for mid-to-high-end conversion.
Use low-price traffic to sell high-priced goods. - Strategy 4 (Unverified): "Nebulization / Steam" as a differentiation cut.
Aux switched to steam nebulization hot compress, priced 329–522 RMB, differentiating in "dry eye" and "post-operative care" scenarios.
Its ceiling depends on one thing: whether "hydration feel" can be translated into a measurable indicator (such as tear film breakup time), otherwise it remains sensory narrative.
Key structural numbers.
In Jan–Sep 2026, EMS pulse + constant-temperature hot compress dual-effect products rose to 45.2% sales share, up 9 percentage points from the previous year.
Silicone material in massage heads reached 76.3%, and portable folding models rose to 28.5% penetration among business travelers.
Q1 cold/hot dual-compress products saw sales up 53.6% MoM, indicating that the dual expectation of "instant soothing + long-term care" is forming.
Daily average use time has reached 18.5 minutes; ages 18–35 contribute 68.9% of sales, while the silver-haired group's product sales growth of 22.1% far exceeds the industry average.
From "RF Replacement Narrative" to "Parameter and Evidence Competition"
The 1064nm near-infrared collagen light was pushed to the forefront precisely in this institutional gap window.
Evidence chains begin to stratify.
Jmoon's transdermal collagen light beauty device published a 12-week exploratory clinical study showing: skin hydration +33.7%, firmness +21.7%, elasticity +22.0%, while erythema and wrinkles decreased.
Philips' "Collagen Red Light Small Iron" supported claims with 28-day measured data from 63 subjects: skin brightness L value +20%, collagen concentration +32%, stratum corneum moisture +67.7%, under-eye wrinkle improvement 20.0%, crow's feet improvement 19.5%, and a physical parameter of red light penetration depth of about 5mm.
These data raised the competitive threshold from "wavelength narrative" to "reproducible human efficacy data + physical penetration parameters."
But the other side is equally real.
A March 2026 cost investigation showed a significant gap between the whole-machine material cost and terminal price of some high-priced collagen light products, raising questions about the actual contribution of optical components to efficacy.
This means the collagen light category in Jan–Sep is simultaneously experiencing "technology upgrading" and "trust discount."
Leading players are accumulating clinical-grade evidence, while white-label and over-marketing brands are consuming the category's credibility.
Regulators still manage non-RF beauty devices as ordinary appliances, prohibiting medical terminology claims, further compressing the space for "borderline medical beauty talk."
The true watershed in 2026 is not "RF or light" but "can it be verified."
RF's exit is essentially not a technology failure; it is that it cannot self-prove safety and dosage in a home scenario.
Light therapy's takeover is not purely a technology victory either; it is that it is easier to photograph, read, and explain.
The next round of competition will push this logic to the extreme: categories that cannot produce data will be classified into the "placebo" narrative.
The parameter arms race has begun.
FOREO's FAQ Dual LED Panel released in September carries 123 professional-grade lamp beads, with a nominal energy density of 200mW/cm² and light source color purity of 99.9%.
Brands on the 1064nm route are beginning to differentiate on underlying optical calibration such as constant-current drive and distributed closed-loop compensation.
However, upstream VCSEL and LED light source localization is accelerating, and simplified optical structures can reduce downstream design costs, with BOM costs having 15%–25% downside space.
When "123 lamp beads" and "200mW/cm²" go from differentiated selling points to standard parameters within 3–6 months, competition will return to clinical evidence quality, safety records, and user actual compliance—three dimensions harder to replicate in the short term.
Claims Exit, Evidence Enters
When the entire category is stuck on the evaluation "effects are not obvious," what can be produced to self-prove becomes the only differentiator.
- Play 01: Move the lab into the livestream.
A Xiaohongshu blogger used an infrared thermal imager to record periocular temperature changes before and after use; a 5℃ difference pushed a review video to 80,000 likes.
The top comment was "This is more convincing than saying 'soothing' a hundred times."
When "real user experience sharing" accounts for 35% of social content, brand money should be spent on translating lab data into consumer language. - Play 02: Turn parameters into visual GIFs.
Breo turned "microcurrent waveforms" into visual GIFs, allowing users to see periocular muscle contraction frequency curves in real time in the APP.
This turns invisible mechanisms into shareable visual assets.
Assets are media; products are content. - Play 03: Cosmetics-device collaboration, borrowing the trust of "device."
GEMO has previously collaborated deeply with clinical brands such as Inno, Lizhuilan, Silly, and Weimei, and in August 2026 collaborated with HiBody (Imeik).
The value of this play is not in the product but in the right to explain: when the instrument is framed with a Class III device, the question "what can home use achieve" is redefined. - Play 04: Celebrity matrix + platform-level title sponsorship.
Jmoon's large iron series gathered multiple celebrities and exclusively sponsored Douyin's "2026 Beautiful Wonderful Night."
The cost is that the mismatch between cost structure and pricing has been publicly questioned: according to media reports, the Large Iron Pro priced at about 1,300 RMB has a whole-machine material cost of less than 100 RMB.
Once such information enters public discussion, it will directly backfire on the legitimacy of premium. - Play 05: Private domain—from selling hardware to selling consumables.
Leading brands' private domain user pools exceed 20 million, paid membership binds consumable repurchases, renewal rate 72%, and private domain channel GMV share rises to 24%.
After hardware margins are compressed by price wars, consumables and services are the only sustainable profit pool. - Play 06: The compliance red line on the content side has been drawn.
On the first day of the new regulation, reporters tested: some brand customer service defined products as "daily beauty care instruments" to avoid qualification inquiries, but detail pages still wrote "full-face wrinkle improvement," "dermal density increase," "improve sagging."
Those who dare to use this vocabulary without a home-use Class III certificate number—no matter what they call their "device"—are high-risk targets.
For the same 100,000 RMB investment, 2025 drove 800,000–1,000,000 GMV, while 2026 drives only 600,000–700,000.
A survey on the eve of Double 11 2026 shows: 79.4% of consumers ask AI before placing an order, and AI's influence on consumption decisions reaches 43.7%, surpassing traditional media advertising for the first time.
Five Cracks Accumulating
| Risk | Exposure | Transmission Path | Observation Window |
|---|---|---|---|
| Efficacy claim overreach | High | Eye care device registration scope is only "relieving visual fatigue," but "reduce prescription" and "replace OK lens" are still circulating → SAMR special rectification → product delisting and fines | Year-round, especially back-to-school season and Double 11 |
| LED blue light safety controversy | Medium-high | After large LED panels took over RF demand, volume expanded; blue light safety controversy not fully resolved, consumer trust repair takes time; industry expects stricter LED phototherapy standards | Q4 promotion period and early 2027 |
| Physical limits of eye safety | Medium | 0.5mm thin skin + pressure + hot compress → negative experiences due to individual differences → public opinion amplification cost far exceeds single-product revenue | Continuous |
| Price war eroding margins | High | 67% of Douyin sales concentrated below 189 RMB → Breo H1 gross margin −3.24pt, net profit −47.1485 million RMB → R&D and content investment compressed | Q3–Q4 financial reports |
| Lack of brand loyalty | Medium-high | Q2 TOP20 new entry rate 65% → single-product lifecycle shortened → repurchase depends on consumables rather than the main unit | Quarterly rankings |
The tail risk of safety incidents cannot be ignored.
The retinal tear incident in October 2025 (a 500-degree myopic user developed a right retinal tear after using high-frequency vibration + high-temperature mode) is still in industry memory, and has promoted the popularization of "high myopia/glaucoma prohibited" warnings.
During Q4 promotions, eye massager sales peaks are accompanied by increased usage intensity.
If new safety incidents occur, platforms may quickly tighten category audits or mandate disclaimers.
This risk is structurally positive for leading brands—compliance costs and safety warning thresholds will accelerate white-label clearance.
But for any single brand, one recall or public opinion incident can offset the entire Q4 marketing investment.
Promotion Cycles Lengthened, Price Wars Administratively Weakened
What everyone sees is "platforms no longer shout low prices"; what is really happening is "low prices can no longer be publicly used as a competitive tool."
| Platform | Mechanism Change | Direct Impact on Categories |
|---|---|---|
| Tmall | Cross-store full reduction canceled, replaced by "official direct discount"; 6 shopping guide apps including "AI Universal Search" and "AI Helps Me Choose" launched; new product merchant count in the month before sale +64% YoY | Stacking logic fails, the design value of sets and bundles decreases, single-product pricing must be right the first time; AI shopping guides make niche parameters (wavelength, penetration depth, Class III certificate number) searchable for the first time |
| JD.com | Deposit pre-sale canceled, focusing on in-stock direct shipping and official direct discounts; first-day order users double-digit YoY growth; service consumption used for differentiation | Favorable for high-ticket categories requiring trust endorsement: certified RF and eye beauty devices convert better on JD than Douyin; at the same time "in-stock" requires early stocking |
| Douyin | No pre-sale, direct discount/one-piece direct reduction, direct 15% discount on registration price; store livestream and AI delivery tools strengthened; first-day million-RMB merchants +74%, new million-RMB products +111% | Price transparency increases, "raise first then discount" space compressed; new product ramp-up still fastest on the entire network, but margins in the sub-189 RMB band further diluted |
What three flattened peaks mean.
Meaning 1: Stocking logic shifts from "betting on peaks" to "smooth supply."
The battle line stretches to one month, and inventory turnover and in-stock rate become more important than single-product explosive power.
Meaning 2: Content delivery window changes from "one day" to "four weeks."
The marginal value of a single hit video declines, and the ability to continuously supply content becomes critical.
Meaning 3: "Off-peak" becomes the only opportunity for small and medium brands.
Leading brands press budgets into Oct 20–Nov 11, while small and medium brands have lower customer acquisition costs in the return period from mid-November to December.
When "lowest price" cannot be shouted, platforms must find new ranking criteria.
The ranking criteria for Q4 2026 are likely: fulfillment certainty > content evidence density > price.
For eye and collagen light categories, this is positive—because the core decision barrier for these products has never been price, but "does it work."
Whoever can answer "does it work" simultaneously on the detail page, short video, and AI Q&A interfaces wins the conversion.
Overseas node hard rules.
US Black Friday/Cyber Monday FBA shipment receiving deadline Oct 28 (based on warehouse receipt, not ship date), China→US ocean freight 40–60 days.
US Deal submission deadline Oct 20; Canada Nov 13; Europe five countries Nov 18.
Black Friday Nov 27, Cyber Monday Nov 30.
Deal price ≤ lowest price in the past 60 days, and additionally 5% below the 30-day lowest price.
FBA peak season surcharge from Oct 15, average +$0.32 per unit, plus 3.5% fuel and logistics surcharge.
Christmas FBA latest receipt falls on Dec 1–8; Christmas goods must sail before mid-November.
Yantian→US West 40HQ express from about $12,000 before National Day to nearly $15,000 on Oct 20, LCL from 11–12 RMB/kg to about 20 RMB/kg.
Six Trend Judgments and Four New Product Directions
High confidence means clear industry signals have emerged; medium-high means leading indicators exist but samples are limited.
- Judgment 01 | Large LED panels/LED continue to take over, but "light safety test reports" become the new ticket.
Q4 shelf competition will shift from "lamp bead count" to "third-party light safety testing."
Actionable: put the test report as the second main image, not hidden at the bottom of the detail page.
Confidence: High. - Judgment 02 | Certified RF maintains price rigidity and does not participate in clearance.
Only 12–13 certified companies, supply scarce, and registration costs must be recovered.
Those expecting "cabbage price" RF devices will likely be disappointed.
Implication for non-RF brands: the 1,500–3,000 RMB vacuum band will persist for 2–3 more quarters, the last window to grab share.
Confidence: Very high. - Judgment 03 | "Massage + light therapy" eye all-in-one is the most certain new increment.
It hits three lines simultaneously: eye massager price band (189–899 RMB), beauty device technology narrative (633/830nm, microcurrent), and regulatory safety boundary (non-RF).
GEMO's AI eye comprehensive device pushes the upper limit above 5,000 RMB, while Breo's dual-spectrum eye care device holds the lower limit at 899 RMB.
The middle ground (1,000–2,500 RMB) is currently empty, the most worthwhile price point to bet on in Q4.
Confidence: High. - Judgment 04 | Gift-giving scenarios take over, average ticket raised by "bundles."
Q4 is the traditional peak season for eye care: dry eye high in autumn/winter, visual fatigue concentrated after school starts, year-end gift demand released.
Feasible combinations: device + eye care gel patches (consumables) + portable storage; or "elder version (large font/voice) + student version (lightweight)" dual-SKU bundle.
Confidence: High. - Judgment 05 | Subscription and consumable binding begin trial in the China market.
The key variable in the international market in 2026 is "SaaS-ification": hardware sold at cost, professional modes unlocked monthly ($10–30).
Risk: Chinese consumers are resistant to "paying again after buying"; Q4 should not do hard subscriptions, but rather "consumable automatic replenishment" soft binding.
Confidence: Medium. - Judgment 06 | Children's eye care track enters a tense period of "strong regulation + high demand."
Demand is extremely strong: the 13-department "Five Health" plan institutionalizes screening frequency, and three departments issued a notice on preventing high myopia in October.
Supply is extremely tight: eye care devices are registered only for "relieving visual fatigue"; "reducing prescription" and "replacing OK lens" are clear violations, and special inspections have been launched in many places.
Conclusion: this is the fastest-growing and most crash-prone segment.
The only compliant path—change the claim from "correct" to "relieve," and the evidence from "cases" to "screening data."
Confidence: Very high.
| Form | Suggested Price | Technical Configuration Points | Opportunity / Risk |
|---|---|---|---|
| Eye light therapy massage all-in-one | 999–2,499 RMB | 633nm red + 830nm near-infrared + constant hot compress (38–42℃) + air pressure/microcurrent; eye mask light-blocking design; 10–15 minutes per session | Biggest opportunity: balances rigid demand and anti-aging narrative. Risk: need to clarify the boundary between "relieve visual fatigue" and "improve eye appearance" claims |
| Cold/hot compress + light therapy dual mode | 599–1,299 RMB | Semiconductor cooling/heating (10-second 30℃ difference) + red light; morning cold compress for de-puffing / night hot compress for sleep dual scenarios | Clear scenario narrative, suitable for short video demos. Risk: insufficient temperature control precision leads to polarized experiences |
| AI recognition eye area device | 3,000–6,000 RMB | AI recognition of eye problem typing + dot matrix current + large light energy chamber (50cm²+) + voice control; with clinical-grade essence | Strongest high-end narrative, can leverage "cosmetics-device collaboration" endorsement. Risk: high clinical evidence requirements, AI functions easily questioned as gimmicks |
| Children/student eye care device | 299–899 RMB | Lightweight head-mounted, adjustable pupillary distance, constant temperature below 40℃, 15-minute timer; parent APP records usage time | Demand certain but claim risk highest. Compliant path: only claim "relieve visual fatigue," use behavioral data rather than "prescription change" as selling point |
Three implicit thresholds for eye products.
Temperature redundancy: surface temperature上限 recommended ≤42℃, with independent thermistor and over-temperature shut-off (industry reference: 39.5℃ cap, 40.5℃ shut-off).
Light safety: must have light-blocking/filtering structure; blue light mode should default off or be set to "requires active activation," and usage duration marked in the manual.
Pressure control: periocular area must not be subjected to continuous pressure; airbag travel and single-session duration (≤15 minutes) need hard limits.
Three Disciplines and a Magnitude Estimate
- Discipline 1: Do not use "raise first, then discount."
"One-piece direct reduction" and "official direct discount" make price anchors public, and platforms regularly spot-check energy parameters and price trajectories.
The Black Cat platform accumulated over a thousand price-related complaints from April to October; the dual cost of regulation and public opinion far exceeds short-term gross profit. - Discipline 2: Hold mid-range price, limit low-end volume, protect high-end narrative.
67% of Douyin sales are below 189 RMB; this segment must be done, but in limited quantity—its role is customer acquisition and content assets, not profit.
The 189–399 RMB band is the best balance of profit and scale (SKG's Q4 share in this band increased 7pt after executing the strategy). - Discipline 3: Stock by "four-week smoothing," not "single-day peak."
Recommend stocking 1.2–1.3x the forecast peak, with a replenishment window in early November.
| Indicator | Q3 Estimate | Q4 Estimate | Basis |
|---|---|---|---|
| Beauty device online retail sales | 1.35–1.50 billion RMB | 2.4–2.8 billion RMB | Q2 (incl. 618) was 1.87 billion; Double 11 cycle longer but peaks flattened, estimated at +70%~+95% MoM |
| Beauty device online average price | ~1,250 RMB | 1,300–1,450 RMB | Certified RF no price cut + higher share of high-end gift models, average price slightly upward |
| Eye massager online GMV | 200–230 million RMB | 340–390 million RMB | Q4 is traditional peak season (autumn/winter dry eye + gifts), usually 35%–38% of full year |
| Eye light therapy/collagen light devices | 120–150 million RMB | 220–280 million RMB | Joint pull from GEMO-type high-end new products and thousand-RMB all-in-one devices |
Estimation note: Q3 absolute value not officially disclosed; inferred from Q1 (1.29 billion), Q2 (1.87 billion) and seasonal coefficients, error may be ±15%.
This table is for magnitude and direction judgment, not a procurement or investment basis.
Three-Scenario Estimate: A Center of 6.8–7.5 Billion RMB
Q4 promotion actual conversion efficiency, and the pace of certified RF brands' return.
Conservative assumes Q4 online YoY decline above 10%; base assumes Q4 +75%–90% QoQ; optimistic assumes eye light therapy all-in-one produces a single-quarter 100-million-RMB hit.
| Quarter | Actual/Estimate | Key Drivers | Confidence |
|---|---|---|---|
| Q1 (Jan–Mar) | 12.9 (actual) | Pre-regulation clearance + March promotion + large LED panel new product ramp; average price 1,523 RMB | High (disclosed) |
| Q2 (Apr–Jun) | 18.7 (actual) | RF delisting → non-RF takeover → 618 pulse; May 900 million RMB peak | High (disclosed) |
| Q3 (Jul–Sep) | 13.5–15.0 (estimate) | Traditional off-season, but back-to-school eye care demand and "certified return" warm-up support | Medium (no official disclosure) |
| Q4 (Oct–Dec) | 24.0–28.0 (estimate) | Double 11 four-week battle + Double 12 + New Year preheating; certified RF no price cut | Medium |
| Full Year | 69.1–74.6 | Rounded to 68–75 billion RMB | — |
Q4 conversion below expectations
Structural rebuilding completed smoothly
Gifts + eye new products both exceed expectations
| Segment | 2025 Base | 2026 Forecast | YoY | Core Variable |
|---|---|---|---|---|
| Beauty devices (all categories) Three-platform merchandise sales | 20.857 billion RMB | 21.5–23.2 billion RMB | +3% ~ +11% | Degree to which RF gap is filled by non-RF; Q4 promotion conversion |
| Eye massagers Online GMV | 786 million RMB | 0.93–1.02 billion RMB | +18% ~ +30% | Continuity of Tmall category +27%; volume of Douyin low-priced models |
| Eye massagers All channels (incl. offline/gifts/cross-border) | ~1.2–1.3 billion RMB | 1.4–1.7 billion RMB | +15% ~ +30% | Offline experience store recovery; gift scenarios; Amazon +68% search growth |
| Eye light therapy / collagen light devices | ~500–700 million RMB | 0.9–1.2 billion RMB | +60% ~ +90% | GEMO-type high-end new products; filling the thousand-RMB all-in-one gap |
Caliber note: the first row "three-platform merchandise sales" and the remaining rows "online retail sales/GMV" are different monitoring systems and cannot be added or subtracted horizontally.
The segmentation of eye categories (massager / light therapy device) currently has no unified industry standard; here divided by "whether it has light therapy function."
The numbers truly worth remembering are structural, not total.
Non-RF technology (light therapy, high current, microcurrent, transdermal collagen light) share will jump from about 45% in 2025 to 62%–68%.
CR5 rises from about 60% to 66%–70%.
TOP20 ranking annual turnover exceeds 100%.
The implication for brands is direct: this year is not won by "making more SKUs," but by "standing on the right technology route + producing evidence + staying compliant."
From "One Superpower, Many Weak" to "Two Superpowers, Many Strong"
| Tier | Representative Brands | Combined Share | Basis |
|---|---|---|---|
| Tier 1 (Two Superpowers) | Jmoon, SEAYEO | 42%–48% | Non-RF routes + channel advantages; but need to defend against certified brand return |
| Tier 2 (Many Strong) | GEMO, YA-MAN, AMIRO, Huazhi, Tripollar | 20%–26% | High-end narrative or certification; return speed determines ceiling |
| Tier 3 (Niche) | MESMOOTH, JOVS, iluminage, etc. | 10%–14% | Value-for-money and niche scenarios |
| Long Tail | White-label / OEM / cross-border small brands | 18%–24% | Low-price band (<189 RMB) mainly, squeezed by platform spot checks and compliance costs |
Eye massager landscape: the dumbbell shape is reinforcing.
Under Taobao sales caliber, Breo holds 25.3% to lead, SKG 11.8%, Aux 3.3%.
In the 500+ RMB mid-to-high-end band, Breo + SKG CR2 exceeds 60%; in the 1,000+ RMB high-end market Breo holds about 80%.
Industry CR5 currently 41.2%; as safety compliance costs rise and supply chain localization cost advantages tilt to leaders, the survival space for small and medium brands in the 200–500 RMB band will be compressed.
Breo's 2025 pre-loss of 84–105 million RMB suggests that high-end positioning itself does not automatically translate into a profit safety cushion.
Users: demand has not changed, decision paths have.
In the past, consumers prioritized influencer recommendations and low-price discounts; now clinical data, medical device registration certificates, and safety sensing functions have become primary decision bases.
Research shows Class III certified products have a 29% higher repurchase rate and 76% lower consumer complaints.
Trust is being assetized.
Gen Z and urban white-collar workers together contribute over 60% of sales; the silver-haired group's demand for "presbyopia assistance" and "chronic dry eye care" is growing rapidly, becoming a new source of average ticket uplift.
Product implication: large font interface, voice control, and single-key operation are not "low configuration" but independent product line opportunities for the silver-haired group.
Regular use rate is the biggest hidden variable.
51% of eye massager users use regularly (≥3 times per week).
Referring to the electric toothbrush adoption path, crossing the 60% threshold will bring about 18% capacity expansion—based on 2025 online 786 million RMB, new scale exceeds 140 million RMB.
This is the highest cost-performance thing for the entire category: no new customers needed, just get existing customers to use it a few more times.
What Else Will Happen Before 2027
Regulatory resources are always directed first to higher-risk areas.
| Topic | Time Window | Probability | Possible Form and Impact |
|---|---|---|---|
| LED phototherapy industry standards | 2027 H1 | Medium-high | Group standards or mandatory light safety testing requirements; blue light limits and usage duration labeling. Impact: white-label clearance, leaders benefit |
| Eye device access refinement | 2027–2028 | Medium | Requirements for periocular temperature control, light safety, pressure limits; may come first as "recommended standards + platform access" |
| Eye care device claim normalization | Continuous | High | "Reduce prescription" and "replace OK lens" continue to be investigated; campus season and back-to-school season are high-incidence windows |
| Myopia prevention policy escalation | Already occurred | Certain | "Five Health" plan (2026–2030) sets 2030 primary school myopia rate ≤32%; three departments issued high myopia prevention notice in October; screening frequency institutionalized |
| Price behavior regulation | Already occurred | Certain | Seven departments' "Five Excellences" action rectifies "automatic price tracking" and "lowest price on the entire network"; platform price comparison and spot checks normalized |
| Advertising endorsement and efficacy proof | 2027 | Medium | Require verifiable sources for "clinical validation" and "medical grade" claims; strengthen joint liability of celebrity endorsements and efficacy claims |
— Fu Jing, Director of Strabismus and Pediatric Ophthalmology, Beijing Tongren Hospital, at the August 2026 "Cherish Vision" eye health science popularization exchange.
These numbers are the underlying support for eye care category demand, and also the most concentrated risk area for false advertising.
- Certainty 1: Concentration continues to rise, but "certified" is no longer a universal card.
Certified RF brands returning will bring 1,500–3,000 RMB back to shelves, but non-RF categories do not need certification, so "certified" is a barrier only in the RF context.
The real barrier is the combination of "clinical evidence + omni-channel + repurchase system." - Certainty 2: Eye device regulation will occur before facial regulation.
The emergence of independent eye-area standards is only a matter of time. - Certainty 3: Going overseas changes from "optional" to "mandatory."
The global home physiotherapy beauty device market is expected to grow from about $5.5 billion in 2025 to $12.4 billion in 2035.
Domestic supply chain advantages + compliance qualification reuse + TikTok content capabilities form a short-window combination advantage. - Variable: AI will rewrite "what is a good product."
When 79.4% of people ask AI before ordering, the product evaluation system becomes parameterized: wavelength, penetration depth, dose, usage frequency, temperature control cap, test report number.
Adjectives will lose weight; verifiable numbers will gain weight.
This is good for the industry—it forces everyone to shift from storytelling to evidence.
It is bad for marketing teams—the copywriting methodology of the past decade must be rewritten.
Twelve Falsifiable Indicators
They constitute the "falsifiable interface" for all judgments in this report—any reverse movement should promptly revise the conclusions.
| Indicator | Source | Current Value / Base | Warning Threshold and Meaning |
|---|---|---|---|
| Beauty device online retail sales | AVC monthly report | Q2 1.87 billion RMB | Q4 below 2.2 billion → conservative scenario holds |
| Industry online average price | AVC | April 1,198 RMB | Falls below 1,150 → price war recurrence, further margin compression |
| TOP1 brand share | AVC | 30.3% (Jmoon) | Falls below 25% → certified brand return effective, landscape reshuffles |
| TOP20 new entry rate | AVC | Q2 65% | Persistently >60% → single-product lifecycle too short, brand assets ineffective |
| Eye massager Tmall category GMV growth | Business Advisor/third party | +27% | Turns negative → category enters stock competition |
| Douyin sub-189 RMB sales share | Chanmama etc. | 67% | >70% → premiumization fails, profit pool dries up |
| Weekly regular use rate (≥3 times) | Shangpu etc. | 51% | Stagnates → capacity expansion logic fails |
| Class III certified companies | NMPA | 12–13 | Rapidly increases to 20+ → RF price rigidity collapses |
| LED light safety standard progress | Standards committee/industry association | Controversy unresolved | Formally立项 → white-label clearance, leaders benefit |
| Eye care device violation penalty cases | SAMR/local bureaus | Continuously increasing | Concentrated exposure → children's line short-term contraction |
| AI decision influence share | Third-party research | 43.7% | >50% → content strategy must be fully structured |
| Leading enterprise R&D expense growth | Listed company reports | 2026H1 +48% | Falls to <20% → innovation cycle peaks |
Six Things, Prioritized
- P0 | Make compliance part of the product, not a cost.
Put qualifications on the main image, make Class III certificates and test reports shareable assets, and put "scope of application" on the first screen of the detail page.
Compliance is not a defensive move; in 2026 it is already the most effective differentiation—because most competitors cannot do it. - P0 | Choose one verifiable technology mainline, don't do an "everything bucket."
"One lamp for whitening + acne + anti-aging" is claim overreach and trust liability.
Conversely, deepening one route (e.g., 633+830nm eye-specific) makes it easier to accumulate clinical and collaboration endorsements. - P1 | Fill the 1,000–2,500 RMB eye gap.
At 899 RMB there is Breo dual-spectrum; above 5,000 RMB there is GEMO AI eye comprehensive; the middle is empty.
This price point can accommodate light therapy, microcurrent, hot compress, and detection functions without touching the Class III threshold. - P1 | Make "usage frequency" a core KPI.
Moving weekly use rate from 51% to 60% equals 18% capacity expansion.
The means is not reminders but reducing friction: hands-free, voice, 3-minute programs, charging base always on. - P2 | Build an "evidence asset library."
Prepare one set of each of the four asset types for year-round reuse: clinical/test data, visual imagery (thermal/waveform), qualification proof, and real user 28-day records.
This is the highest-priority infrastructure for the content team. - P2 | Use consumables and services to rewrite the profit structure.
Hardware margins compressed by price wars is a long-term trend.
Eye care gel patches, essence, light-blocking eye masks, and annual card services are the key to turning one-time transactions into cash flow.
Private domain renewal rate of 72% has proven feasible.
Treat "eye care" as an independent category that needs to be redone, not as a "shrunk-down version of facial devices."
Periocular skin 0.5mm, sensitive intraocular pressure, high dry eye incidence, and two extreme groups—children and the silver-haired—these constraints determine the entire difference in product definition, content claims, and compliance boundaries.
The real opportunity in 2026 is not in "stronger," but in "more suitable for the eyes."
Looking back, whoever had a non-RF BOM contingency plan survived.
But it is true. We redesigned our detail page three times this year, all toward evidence.
Air freight costs a lot more per kilo, but stockout weight loss is even more expensive.
High myopia and glaucoma patients really should not use high-frequency vibration plus high-temperature mode.
Otherwise Q4 gross margin will be eaten by upstream.
But content assets still have to be there, just in a different form.
The hardest part of making an all-in-one is the boundary between "relieve visual fatigue" and "improve eye appearance"—one slip and you cross the line.
TOP20 annual turnover over 100% means this track is now buying "quarters," not "companies."
Coupang leans 3C/appliances, Olive Young leans beauty/personal care; one set of goods for both channels basically does not work.
6–12 month cycle; file now and you can catch Black Friday 2027.
Photobiological safety and biocompatibility are the two easiest to get stuck on.